GlassScriptPhysician profile
David K Kaufman
NPI 1114942604
$2,708.40
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $263 · 2021: $593 · 2022: $483 · 2023: $424 · 2024: $37.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $634.69 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $286.74 | 2019-2020 | |
| Emd Serono, INC. | $201.07 | 2019-2023 | Mavenclad |
| Abbvie INC. | $136.99 | 2021-2023 | |
| Allergan, INC. | $129.26 | 2019-2022 | |
| Biogen, INC. | $107.42 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $102.01 | 2022-2023 | Dysport |
| Genentech USA, INC. | $93.42 | 2019-2023 | Ocrevus, Enspryng |
| Teva Pharmaceuticals USA, INC. | $74.46 | 2019-2023 | Austedo Xr |
| Lilly USA, LLC | $69.82 | 2019-2023 | Reyvow, Emgality |
| Neurocrine Biosciences, INC. | $68.32 | 2019-2021 | |
| Livanova USA, INC. | $66.69 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $60.05 | 2019-2020 | |
| Argenx US, INC. | $49.40 | 2023 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $48.36 | 2019-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $43.73 | 2019-2022 | |
| Lundbeck LLC | $36.13 | 2019-2023 | Vyepti |
| Ucb, INC. | $35.16 | 2022-2024 | Rystiggo |
| Horizon Therapeutics Plc | $33.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $32.08 | 2022 | |
| Alexion Pharmaceuticals, INC. | $29.94 | 2020-2022 | |
| Celgene Corporation | $27.88 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $27.40 | 2022 | |
| Merz North America, INC. | $26.29 | 2019-2020 | |
| Corium, LLC | $24.98 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $24.58 | 2021 | |
| Kedrion Biopharma, INC. | $21.88 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Koate |
| Banner Life Sciences, LLC | $21.66 | 2022 | |
| Genzyme Corporation | $20.54 | 2019 | |
| Tg Therapeutics, INC. | $19.96 | 2023 | |
| Csl Behring | $18.49 | 2019 | |
| Medtronic, INC. | $18.01 | 2022 | |
| Saol Therapeutics INC. | $17.80 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.06 | 2022 | |
| Tanabe Pharma America, INC. | $15.64 | 2019 | |
| Strongbridge US INC. | $15.44 | 2019 | |
| Medtronic USA, INC. | $15.33 | 2020 | |
| Vertical Pharmaceuticals, LLC | $12.87 | 2019 | |
| Kyowa Kirin, INC. | $12.25 | 2019 | |
| Eisai INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.